New Approaches to the Adoptive Immunotherapy of Established Metastatic Cancer using Lymphokine-Activated Killer Cells and Recombinant Interleukin-2

This publication has 11 references indexed in Scilit:

• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• The human mixed lymphocyte-tumor cell interaction test
  Cancer Immunology, Immunotherapy, 1984
• Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
  Science, 1984
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
  The Journal of Experimental Medicine, 1983
• The fate of interleukin-2 after in vivo administration.
  The Journal of Immunology, 1983
• Structure and expression of a cloned cDNA for human interleukin-2
  Nature, 1983
• In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
  The Journal of Immunology, 1980
• Passive Immunotherapy of Cancer in Animals and Man
  Published by Elsevier ,1977